SynthesisJAMA oncology2023

Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.

Anke Richters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.